Sami Aboumatar, MD
Neurology · Austin, TXNPI 1760445407
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by SK Life Science, Inc. at 51.1% of the total. Reporting peaked in 2019 at $25,657 and has fallen 69.3% since, to $7,882 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 448 payments — averaging $197.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$45K
- Aquestive Therapeutics, Inc.$23K
- UCB, Inc.$11K
- Eisai Inc.$2K
- Greenwich Biosciences, Inc.$2K
- Sunovion Pharmaceuticals Inc.$1K
- plus $4K from 34 others
Across 202 payments — averaging $2656.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$149K
- Sunovion Pharmaceuticals Inc.$96K
- Aquestive Therapeutics, Inc.$91K
- Jazz Pharmaceuticals Inc.$54K
- UCB SA$53K
- UCB Biosciences Inc.$42K
- plus $52K from 4 others
What the payments were for
- Consulting fees$31,12035%
- Speaking & faculty fees$40,27046%
- Travel & lodging$7,1978%
- Food & beverage$9,80011%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$38,104
- SYMPAZAN$21,934
- Fintepla$8,884
- Cenobamate$2,175
- Fycompa$2,025
- Epidiolex$1,958
- APTIOM$1,175
- Briviact$374
- RNS System$129
How this compares
$88,474 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 257 | $836,551 |
| XcopriCenobamate | 416 | $573,213 |
| BriviactBrivaracetam | 229 | $421,150 |
| FinteplaFenfluramine Hcl | 29 | $341,305 |
| AptiomEslicarbazepine Acetate | 85 | $246,619 |
| FycompaPerampanel | 140 | $226,856 |
| ZonegranZonisamide | 57 | $198,292 |
| Lacosamide | 715 | $110,501 |
| VimpatLacosamide | 43 | $84,307 |
| Lamictal XrLamotrigine | 24 | $72,813 |
| OnfiClobazam | 34 | $72,069 |
| Clobazam | 498 | $70,975 |
| Rufinamide | 59 | $66,335 |
| TopamaxTopiramate | 23 | $51,396 |
| Lamotrigine ErLamotrigine | 105 | $48,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Fintepla, Vimpat, Nayzilam | $11,219 | $878,057329 claims |
| SK Life Science, Inc.Xcopri | $45,203 | $573,213416 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,351 | $246,61985 claims |
| Eisai Inc.Fycompa | $2,367 | $226,856140 claims |
| Lundbeck LLCOnfi | $64 | $72,06934 claims |
| Neurelis, Inc.Valtoco | $100 | $34,37227 claims |
| AbbVieQulipta | $327 | $13,98911 claims |
| PfizerDilantin | $196 | $8,90052 claims |
| Upsher-smith Laboratories LLCTopiramate | $33 | $7,467323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Austin
- Elliot FrohmanAustin$381K
- Krishna PokalaAustin$143K
- Subhashie SarathkumaraAustin$129K
- David MorledgeAustin$128K
- Stephanie VertreesAustin$119K
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.